Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether all products considered by the Accelerated Access Collaborative will have to be cost-neutral to the NHS.

As it continues to drive forward the assessment and uptake of the best products for support, the Accelerated Access Collaborative (AAC) has been empowered to be flexible and pragmatic enough to identify truly game-changing innovations, that may not be cost-neutral in year, but are assessed by the National Institute for Health and Care Excellence to be both clinically and cost-effective. This will allow the AAC to identify products, or classes of products, that are most likely to significantly transform care in the National Health Service.